Clinical Trial Update: Efficacy and Safety Study of Sirukumab in Subjects With Polymyalgia Rheumatica [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the efficacy and safety of sirukumab in polymyalgia rheumatica was withdrawn by the sponsor.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polymyalgia Rheumatica

Drugs mentioned

• Sirukumab (sirukumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Polymyalgia Rheumatica | Phase 3 | Status: WITHDRAWN